Previous 10 | Next 10 |
G1 Therapeutics receives FDA acceptance of its Small Cell Lung Cancer NDA G1 Therapeutics Inc. ( GTHX ) reported that the FDA has accepted its New Drug Application of its lead drug candidate, Trilaciclib. The FDA has given Priority Review status to the NDA, and the PDUFA action date has ...
VANCOUVER, Washington, Aug. 18, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...
CytoDyn ( OTCQB:CYDY ) has provided its top-line report from its recently completed Phase 2 clinical trial for patients with mild-to-moderate COVID-19 symptoms to regulatory authorities in U.K. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
VANCOUVER, Washington, Aug. 18, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...
CytoDyn ( OTCQB:CYDY ) announces that it plans to conduct a five-subject pilot study evaluating leronlimab in HIV-infected patients who require bone marrow transplantation. The CCR5-blocking antibody will be used during the peri-transplant period to mimic a CCR5-deficient donor aimed at ...
HIV monotherapy trials update: 215 patients completed almost one year of monotherapy. Only some were allowed to continue in extension arm; five patients reached almost 6 years. Twenty-five reached 2 to 4 years and 20 patients are 1 to 2 years VANCOUVER, Washington, Aug. 17, 2020 (GLOBE...
The Top-line Report has been sent to the regulatory authorities in Mexico, and will be provided to U.K. MHRA, and E.U. EMA, with requests for emergency use approval CytoDyn is preparing a Phase 3 protocol for leronlimab use in long-hauler COVID-19 individuals VANCOUVER, Washing...
The CV-19 pandemic shows no signs of slowing. To date, there are nearly 21 million cases, with 769,235 deaths. In the U.S., cases are up to 5.25 million. Brazil is up to 3.22 million. India is nearing 2.5 million. Russia is now up to 910,778. Meanwhile, the World Health Organization has warne...
FinancialBuzz.com News Commentary New York, NY (8/13/2020) – With over 5 million people confirmed to be infected with the virus in the United States alone, the pandemic has made it vital for hospitals to diagnose patients early and monitor their health in real time, limiting contact bet...
Notes from today's conference call at CytoDyn ( OTCQB:CYDY ) regarding the results from a Phase 2 clinical trial evaluating leronlimab in COVID-19 patients with mild-to-moderate symptoms. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...